Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...

Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

In the latest trading session, Novo Nordisk (NVO) closed at $69.30, marking a -1.23% move from the previous day.

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Novo Nordisk shares are experiencing a significant decline amidst intensified investor concerns over its competitiveness in ...

In September 2023, the Danish pharmaceutical business became the most valuable company in Europe by market capitalization due ...

Danish biotech giant Novo Nordisk is trading at an extremely attractive valuation — particularly relative to its main rival, ...

Danish pharma major Novo Nordisk (NOV: N) has taken another step in its strategy to maintain dominance in the obesity space by adding complementary mechanisms to pair with its blockbuster bGLP-1 ...

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...